CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development

Issuer: CureVac / Key word(s): Study28.05.2024 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK  Phase 2 study to assess updated formulations for im...

Related Keywords

Germany ,United States ,Belgium ,Switzerland ,Netherlands ,Patrick Perez ,Sarah Fakih ,Myriam Mendila ,Development In Collaboration ,Junior ,Curevac Corporate Services Gmb ,Corporate Communications ,World Health Organization ,Curevac Inc ,Exchange Commission ,Distribution Services ,Vac Announces Dosing ,First Participant ,Seasonal Influenza ,Chief Scientific Officer ,Junior Manager Public ,Vice President Corporate Communications ,Curevac Manufacturing Gmbh ,Curevac Swiss ,Curevac Corporate Services Gmbh ,Curevac Belgium ,Corporate News ,Regulatory Announcements ,